Publicaciones en colaboración con investigadores/as de Medical University of Vienna (29)

2023

  1. Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial

    European Journal of Cancer, Vol. 184, pp. 48-59

2022

  1. Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 3, pp. 282-293

  2. Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial

    Frontiers in Oncology, Vol. 12

  3. Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients

    European Journal of Cancer, Vol. 166, pp. 185-201

  4. Multiple Bayesian network meta-analyses to establish therapeutic algorithms for metastatic triple negative breast cancer

    Cancer Treatment Reviews, Vol. 111

  5. Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

    European Journal of Cancer, Vol. 168, pp. 12-24

2021

  1. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

    Annals of Oncology, Vol. 32, Núm. 12, pp. 1571-1581

  2. Anthracyclines strike back: Rediscovering non‐pegylated liposomal doxorubicin in current therapeutic scenarios of breast cancer

    Cancers, Vol. 13, Núm. 17

  3. Expected medium- And long-term impact of the COVID-19 outbreak in oncology

    JCO Global Oncology, Vol. 7, pp. 162-172

  4. Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial

    Clinical Breast Cancer, Vol. 21, Núm. 1, pp. 80-91.e7

  5. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

  6. Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer-The Penelope-B Trial

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 39, Núm. 14, pp. 1518-1530

  7. Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

    Annals of Oncology, Vol. 32, Núm. 4, pp. 488-499

  8. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

    The Lancet Oncology, Vol. 22, Núm. 2, pp. 212-222

  9. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Oncological care organisation during COVID-19 outbreak

    ESMO Open, Vol. 5, Núm. 4

2019

  1. Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: Longitudinal analyses from the randomized phase III ExteNET trial

    Annals of Oncology, Vol. 30, Núm. 4, pp. 567-574

  2. PIK3CA alterations and benefit with neratinib: Analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial

    Breast Cancer Research, Vol. 21, Núm. 1

  3. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone

    Breast Cancer Research and Treatment, Vol. 176, Núm. 2, pp. 377-386

2017

  1. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

    The Lancet Oncology, Vol. 18, Núm. 12, pp. 1688-1700